Therapeutic and pre-clinic efficacy has been shown in models of rheumatoid arthritis and inflammatory bowel disease.28 However, according to our results, future therapeutic approaches targeting NF-κB will need to carefully consider the protective functions of the NF-κB subunit p50 (NF-kB1) during the onset of acute renal injury. Here, NFKB1 is linked to inflammatory bowel disease.